Glenn Bubley is an Oncology physician affiliated with Beth Israel Deaconess Medical Center. OpenAlex indexes 443 publications with 47,102 citations (h-index 79); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 Brookline Ave
Him-1049
Boston, MA 022155400
Telephone
617-667-5288Registry record last updated 8 Jul 2007.
Clinical trials
- Enzalutamide + External Beam Rt For Prostate
Sponsor: Dana-Farber Cancer Institute
- BKM120+Abiraterone Acetate for Metastatic CRPC
Sponsor: Dana-Farber Cancer Institute
- Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Sponsor: Beth Israel Deaconess Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments
- PFIZER INC.Program year20246 payments
- PFIZER INC.Program year20238 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Gonadotropin Releasing Hormone Receptor Antagonist100%Orgovyx100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 1987–2013 per NIH RePORTER. The latest:
- TRIAL OF PFHUK5 IL 2 IMMUNOCYTOKINE FUSION IN PROSTATE CARCINOMA
Beth Israel Deaconess Medical Center
FY2002M01RR001032
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Matcheri Keshavan, MD
Beth Israel Deaconess Medical Center
Connie Tsao, MD
Beth Israel Deaconess Medical Center
Donald Cutlip, MD
Beth Israel Deaconess Medical Center
Robert Yeh, MD
Beth Israel Deaconess Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”